Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ SHMT2 Monoclonal Antibody (OTI1E12)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA527057
Description
SHMT2 Monoclonal Antibody for Western Blot, IHC (P)
Mammalian serine hydroxymethyltransferase (SHMT) is a tetrameric, pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the reversible interconversion of serine and tetrahydrofolate to glycine and methylenetetrahydrofolate in the cytoplasm (cSHMT, SHMT1) and mitochondria (mSHMT, SHMT2). cSHMT preferentially supplies one-carbon units for thymidylate biosynthesis, depletes methylenetetrahydrofolate pools for S-adenosylmethionine (SAM) synthesis by synthesizing serine, sequesters 5-methyltetrahydrofolate, and inhibits SAM synthesis.
Specifications
SHMT2 | |
Monoclonal | |
1 mg/mL | |
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3 | |
P34897, Q9CZN7 | |
SHMT2 | |
Full length human recombinant protein of SHMT2 produced in E.coli. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG1 |
Immunohistochemistry (Paraffin), Western Blot | |
OTI1E12 | |
Unconjugated | |
SHMT2 | |
2700043D08Rik; AA408223; AA986903; epididymis secretory sperm binding protein Li 51e; GLY A+; GLYA; glycine auxotroph A, human complement for hamster; glycine hydroxymethyltransferase; HEL-S-51e; mitochondrial serine hydroxymethyltransferase; serine aldolase; serine hydroxymethylase; serine hydroxymethyltransferase; serine hydroxymethyltransferase 2; serine hydroxymethyltransferase 2 (mitochondrial); serine hydroxymethyltransferase, mitochondrial; Serine methylase; SHMT; SHMT 2; SHMT2; threonine aldolase | |
Mouse | |
Affinity chromatography | |
RUO | |
108037, 299857, 6472 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction